Our project has been selected for the AMED's “Research Project for Practical Application of Innovative Cancer Therapy”.

Our research using TBP1901, a drug we have developed, has been selected for the “Research Project for Practical Application of Innovative Cancer Therapy” (Field 3-1) for fiscal year 2025, with the Japan Agency for Medical Research and Development (AMED) as the project sponsor. (Project title: “Preclinical Research on TBP1901, a Prodrug-type Anticancer Drug for Multiple Myeloma, Aiming to Overcome Drug Resistance and Side Effects”)

The research will be led by our Scientific Advisor, Professor Masashi Kanai of Kansai Medical University, and will conduct non-clinical studies with the aim of completing preparations for the entry into clinical trials and out-licensing of TBP1901, a new cancer drug.